HYPHENS PHARMA INTL LIMITED (1J5) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of HYPHENS PHARMA INTL LIMITED S$0.40, price S$0.37, upside +8.1%, quality 74 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch HYPHENS PHARMA INTL LIMITED for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Hyphens Pharma International Limited, together with its subsidiaries, operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, Malaysia, and internationally. It operates through Pharmaceutical and Medical Aesthetics; Proprietary Brands; and Digital Platform and E-Pharmacy segments.
Show more
Hyphens Pharma International Limited, together with its subsidiaries, operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, Malaysia, and internationally. It operates through Pharmaceutical and Medical Aesthetics; Proprietary Brands; and Digital Platform and E-Pharmacy segments. The Pharmaceutical and Medical Aesthetics segment markets and sells a range of pharmaceutical and medical aesthetics products, including the Stérimar nasal sprays, Bausch+Lomb eye drops, Vivomixx, Fenosup Lidose, and Piascledine products in ASEAN countries. This segment focuses on various therapeutic areas, such as dermatology, pediatrics and neonatology, allergy, otorhinolaryngology, orthopedics and rheumatology, radiology, cardiology and interventional cardiology, ophthalmology, gastroenterology, psychiatry, family medicine, and medical aesthetics. Its Proprietary Brands segment develops, markets, and sells dermatological products comprising Ceradan, TDF, and CG210; health supplements under the Ocean Health brand covering areas, such as heart, joint, physical, cognitive, eye, and health; and pharmaceuticals. The Digital Platform and E-Pharmacy segment operates a digital platform that services procurement needs of healthcare professionals, healthcare institutions, and retail pharmacies primarily in Singapore. The company was formerly known as Hyphens Pharma International Pte Ltd and changed its name to Hyphens Pharma International Limited in May 2018. Hyphens Pharma International Limited was founded in 1998 and is headquartered in Singapore.
Stock analysis
HYPHENS PHARMA INTL LIMITED (1J5) currently trades at 0.3700 SGD, while our model-based Fair Value estimate is 0.4000 SGD, so the stock looks roughly fairly valued today (gap 7.5%).
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 0.7100 SGD per share, and 16 of the 24 models we run sit above the 0.3700 SGD price.
Bear case: the Earnings-Based group reads lowest at 0.1200 SGD, and 8 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: 0.3000 SGD (bear) to 0.5000 SGD (bull), the price of 0.3700 SGD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 74/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
HYPHENS PHARMA INTL LIMITED reported revenue of 177M SGD in FY2025 versus 126M SGD in FY2021, a compound +8.9%/yr. Reported net income was 5.8M SGD in FY2025, compounding −3.9%/yr from FY2021.
Key figures
Market cap 114M SGD (≈ $89.2M) · P/E ratio 18.5 · P/S ratio 0.61 · EPS (TTM) 0.0200 SGD · Dividend yield 4.1% · Net margin 3.3% · Return on equity 8.3% · Return on assets (EBIT) 11.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).
What moves the price
The share trades about 1% below its 52-week high and 29% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 37% fair-value upside, at 8%, 1J5 screens richer than that median.
Fair Value models
Bear 0.3000 SGDFair Value 0.4000 SGDBull 0.5000 SGD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.0038 SGD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.69/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−9.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.5%
Start year 2020 (pandemic). Over 10 years: +8.5% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.5%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
+16.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+11.9%
Dividend (yield on the price)4.1%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.8% → 9%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−11.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Singapore: IMF forecast 2.0% a year to 2030, 1.7% from 2016 to 2025) that is about −13.1% a year for the price.
Compare HYPHENS PHARMA INTL LIMITED with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 77 stocks
Beats the industry median on 10/15 measures
Overall it ranks above its industry peers.
Valuation
Quality Score74 · Top 25%
Fair Value upside+8.1% · Above median
Profitability
Return on equity (TTM)8.3% · Above median
Return on assets5.7% · Top 25%
Net margin (TTM)3.3% · Above median
Operating margin (TTM)8.0% · Top 25%
Growth and dividend
Revenue growth−15.4% · Bottom 25%
Dividend yield (TTM)4.1% · Above median
Balance sheet
Debt / equity0.04× · Below median
Valuation Multiplesvs Medical Distribution median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is HYPHENS PHARMA INTL LIMITED (1J5) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of 0.4000 SGD versus a price of 0.3700 SGD, about +8% upside (fairly valued).
What is the fair value of 1J5?
Our model-based fair value for HYPHENS PHARMA INTL LIMITED is 0.4000 SGD (as of Sep 27, 2026), built from audited fundamentals. The current price: 0.3700 SGD.
What is the quality score of 1J5?
HYPHENS PHARMA INTL LIMITED has a Quality Score of 74/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for HYPHENS PHARMA INTL LIMITED (1J5)?
Our model-based price target is the fair value of 0.4000 SGD (as of Sep 27, 2026) from 24 valuation models. Cautious scenario 0.3000 SGD, optimistic scenario 0.5000 SGD. It is a calculation from audited fundamentals, not an analyst target.
What is the HYPHENS PHARMA INTL LIMITED stock forecast for 2026?
Our models put fair value at 0.4000 SGD, about +8% upside versus a price of 0.3700 SGD (fairly valued). Cautious scenario 0.3000 SGD, optimistic scenario 0.5000 SGD. The calculation is refreshed regularly with new filings.
What is the revenue of HYPHENS PHARMA INTL LIMITED (1J5)?
HYPHENS PHARMA INTL LIMITED reported trailing-twelve-month revenue of about 177M SGD (latest available figure, as of Sep 27, 2026).
Does HYPHENS PHARMA INTL LIMITED pay a dividend?
HYPHENS PHARMA INTL LIMITED currently shows a dividend yield of about 4.05% relative to its recent price (as of Sep 27, 2026).
What growth is priced into HYPHENS PHARMA INTL LIMITED (1J5)?
For today's price to be fair in a discounted-cash-flow model, HYPHENS PHARMA INTL LIMITED would have to grow free cash flow by -11.4 % per year for five years (discount rate 11.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.5 % per year. As of Sep 27, 2026.
What discount rate (WACC) does the fair value of 1J5 use?
Our models discount HYPHENS PHARMA INTL LIMITED at 11.0 %: a base by market capitalisation (micro), damped by beta 0.22, country premium for Singapore. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For HYPHENS PHARMA INTL LIMITED that is -11.4 % per year a year over ten years, using the same discount rate (11.0 %) and the same formula as our fair value.
How much growth has HYPHENS PHARMA INTL LIMITED (1J5) delivered so far?
Over the past 5 years revenue at HYPHENS PHARMA INTL LIMITED grew +7.5 % a year. The price currently implies -11.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of HYPHENS PHARMA INTL LIMITED (1J5) growing?
The median revenue growth in the sector is +3.1 % a year. That is the yardstick for the growth priced into HYPHENS PHARMA INTL LIMITED (-11.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of HYPHENS PHARMA INTL LIMITED (1J5)?
The free-cash-flow yield on the price is 15.30 %: that much free cash flow HYPHENS PHARMA INTL LIMITED produces per unit of market value. When it exceeds the discount rate of our models (11.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of HYPHENS PHARMA INTL LIMITED (1J5)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For HYPHENS PHARMA INTL LIMITED it is 0.4000 SGD per share (as of Sep 27, 2026), against a price of 0.3700 SGD. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is HYPHENS PHARMA INTL LIMITED stock overvalued or undervalued in 2026?
As of Sep 27, 2026, 1J5 trades below its calculated fair value: price 0.3700 SGD, fair value 0.4000 SGD, a gap of about +8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1J5?
No. The price is what the market pays today (0.3700 SGD); the fair value is what the company's own numbers justify (0.4000 SGD). For HYPHENS PHARMA INTL LIMITED the two are 0.0300 SGD per share apart. That gap is exactly why we show both numbers side by side.
How much is HYPHENS PHARMA INTL LIMITED worth?
The market values HYPHENS PHARMA INTL LIMITED at about 114M SGD (market capitalisation, as of Sep 27, 2026). Per share that is 0.3700 SGD; our models calculate a fair value of 0.4000 SGD per share.
What do the bullish and bearish scenarios say about 1J5?
Our models span a range for HYPHENS PHARMA INTL LIMITED: cautious scenario 0.3000 SGD, base 0.4000 SGD, optimistic 0.5000 SGD per share (as of Sep 27, 2026, price 0.3700 SGD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1J5?
HYPHENS PHARMA INTL LIMITED trades at a price-to-earnings ratio of 18.5 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 0.4000 SGD is built from several models across several years. Other multiples: PEG 0.9, P/B 1.6, P/S 0.6, EV/EBITDA 6.7.
What is the PEG ratio of 1J5?
The PEG ratio of HYPHENS PHARMA INTL LIMITED is 0.90 (P/E divided by earnings growth, as of Sep 27, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of HYPHENS PHARMA INTL LIMITED (1J5)?
Balance-sheet figures for HYPHENS PHARMA INTL LIMITED (as of Sep 27, 2026): return on equity 8.3%, debt of 0.04 per unit of equity. They feed the Quality Score of 74/100, which measures business quality independently of the share price.
How far is 1J5 from its 52-week high?
HYPHENS PHARMA INTL LIMITED trades at 0.3700 SGD, about 1% below its 52-week high of 0.3750 SGD and 29% above the low of 0.2873 SGD (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of 0.4000 SGD is for.
Which stocks are comparable to HYPHENS PHARMA INTL LIMITED?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is HYPHENS PHARMA INTL LIMITED stock attractive at the current price?
The data as of Sep 27, 2026: price 0.3700 SGD, calculated fair value 0.4000 SGD (+8%), Quality Score 74/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1J5 calculated?
We run HYPHENS PHARMA INTL LIMITED through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.4000 SGD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. HYPHENS PHARMA INTL LIMITED currently trades 8 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of HYPHENS PHARMA INTL LIMITED (1J5)?
The closing price on Oct 1, 2026 was 0.3700 SGD. Our model-based fair value is 0.4000 SGD, about +8% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with HYPHENS PHARMA INTL LIMITED right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of HYPHENS PHARMA INTL LIMITED
How large is the market capitalisation of HYPHENS PHARMA INTL LIMITED (1J5)?
The market capitalisation of HYPHENS PHARMA INTL LIMITED is 114M SGD (≈ $89.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of HYPHENS PHARMA INTL LIMITED (1J5)?
The price-to-sales ratio of HYPHENS PHARMA INTL LIMITED is 0.61 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of HYPHENS PHARMA INTL LIMITED (1J5)?
Earnings per share at HYPHENS PHARMA INTL LIMITED are 0.0200 SGD (price ÷ EPS = P/E 18.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of HYPHENS PHARMA INTL LIMITED (1J5)?
The dividend yield of HYPHENS PHARMA INTL LIMITED is 4.1% (payout 75.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of HYPHENS PHARMA INTL LIMITED (1J5)?
The net margin of HYPHENS PHARMA INTL LIMITED is 3.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of HYPHENS PHARMA INTL LIMITED (1J5)?
The return on equity (ROE) of HYPHENS PHARMA INTL LIMITED is 8.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of HYPHENS PHARMA INTL LIMITED (1J5)?
On an EBIT basis the return on assets of HYPHENS PHARMA INTL LIMITED is 11.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of HYPHENS PHARMA INTL LIMITED (1J5)?
The operating margin of HYPHENS PHARMA INTL LIMITED is 8.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at HYPHENS PHARMA INTL LIMITED (1J5)?
Revenue at HYPHENS PHARMA INTL LIMITED is growing −15.4% versus a year earlier (3y avg +3.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at HYPHENS PHARMA INTL LIMITED (1J5)?
Earnings per share at HYPHENS PHARMA INTL LIMITED are growing −23.2% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch HYPHENS PHARMA INTL LIMITED in the live analysis
One click puts HYPHENS PHARMA INTL LIMITED on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
